Webcasts

Wednesday, November 3, 2021 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET

JDeep learning algorithms have become a standard tool in many industries ranging from e-commerce to healthcare. Their ability to translate data into intelligent predictions completely transformed these industries, increasing productivity and controlling costs. These successes sometimes obscure inherent vulnerability of these models such as difficulty in generalizing in the presence of distribution shifts and ineffectiveness in estimating confidence of their prediction

Robust and Trustworthy Machine Learning Algorithms for Real Work Applications

***Live: Wednesday, October 27, 2021 at 11am EDT ***  “Next best” suggestions are widely seen as the tools most likely to solve the challenge of omnichannel orchestration. In this webinar, we will look at the approaches taken across the industry to implement next best programs, and what drives their success as well as what stops them from delivering on expectations.

Using Next Best to Elevate your Omnichannel Marketing Strategy

***Live: Tuesday, October 26, 2021 at 11 EDT | 8am PDT | 5pm CEST | 4pm BST***  Oracle Health Sciences reveals new research conducted to understand the technology adaptations that were made to clinical trials during the pandemic, the effect of these adaptations, and the impact of these changes on the future of clinical trials.

2021 Research: The Impact of New Clinical Trial Approaches Adopted During Pandemic

***Live: Thursday, October 21, 2021 at 11am EDT***  Join this webinar to learn how leading organizations are recognizing opportunities to transform commercial operations with embedded compliance and data-driven insights.. ***On demand available after final airing until Oct. 21, 2022***

Is Compliance Slowing You Down? Utilize Embedded Compliance to Accelerate Better Business Outcomes

Christian K Schneider, M.D., is Head of Biopharma Excellence and Chief Medical Officer (Biopharma) at PharmaLex. He was previously interim Chief Scientific Officer at the UK’s MHRA, where he was also Director of the National Institute for Biological Standards and Control (NIBSC) for five years. He has also held leading positions at the Danish Medicines Agency and at the Paul-Ehrlich-Institut, Germany’s Federal Agency for Vaccines and Biomedicines.

At EMA, he has chaired the Committee for Advanced Therapies (CAT) as well as the Biosimilar Medicinal Products Working Party (BMWP), and served as a member of the Committee for Medicinal Products for Human Use (CHMP). He is one of the key architects of EMA’s advanced therapies and biosimilars framework. As a regulatory scientist, Christian has published 50+ articles in international, peer-reviewed journals.



Articles

While advanced therapy medicinal products (ATMPs) hold great promise, the path to exploiting the technology has been challenging. Christian K. Schneider outlines the five strategies that must be considered to increase the success rates of development programs, while avoiding some of the common pitfalls.





Streamlining the Path to Market for Novel Therapies: 5 Strategies for Success

Tuesday, October 12, 2021 at 1pm EDT | 10am PDT | 6pm BST
We’re at a tipping point: patient engagement is now a key area of focus, and life sciences companies will be able to differentiate by shifting away from traditional models and embracing platforms that uniquely combine high tech with high touch. Join Andrea Heslin Smiley, President and CEO of VMS BioMarketing, the leading provider of patient adherence solutions, for a discussion on how the industry is rapidly transforming how it engages with its end customers.

How Pharma is Reinventing Patient Engagement

***Live: Thursday, October 7, 2021 at 11am EDT***  Join this webinar to learn how exceptional experiences can redefine value and drive higher performance. ***On demand available after final airing until Oct. 7, 2022***

It is Time to Rethink Engagement: Customer expectations have Changed. Have you?

Tuesday, October 5, 2021 at 2pm EDT | 11am PDT | 7pm BST | 8pm CEST
True patient-centricity requires a new approach to data and insights, requiring deep integration into the fabric of the Life Sciences enterprise. Register for this webinar to learn more about the power of real-time, patient-level data throughout every step of the brand lifecycle – from R&D to commercialization and beyond.

The Power of Real- World Data From Launch & Beyond 

This webcast will showcase how rare disease franchises can successfully utilize ML/AI to increase sales velocity, improve patient lifetime value and accelerate time to peak revenue. Attendees will hear how IPM.ai partnered with Kyowa Kirin to implement ML/AI-based patient finding for its X-linked hypophosphatemia (XLH) therapy to uncover undiagnosed patients, better understand the patient treatment journey and trigger highly accurate field intelligence for salesforce optimization. IPM.ai and Kyowa Kirin will share best practices for rare disease businesses seeking to implement ML/AI for optimized commercial and patient outcomes.

Building a Rare Disease Business: How ML/AI Optimizes Commercial and Patient Outcomes

Tuesday, September 28, 2021
Market forces are accelerating to pressure both demand and margin. In this webinar, we will examine several specific demand and margin factors that impact brand performance, including a data driven perspective of current macroeconomic trends in healthcare, the impact of growing payer control and patient cost sharing on brand performance, how increased complexity of the patient experience changes the need for patient support, and an overview of policy considerations to have on your radar.